Document is current
Any future updates will be listed below
-
Authors
Cooper, Rachel https://orcid.org/0000-0003-3370-5720
Hurst, Christopher https://orcid.org/0000-0002-7239-6599
Syddall, Holly https://orcid.org/0000-0003-0171-0306
Atkinson, Helen
Bunn, Jonathan G. https://orcid.org/0000-0001-9414-9903
Carpinelli, Daniela
Granic, Antoneta https://orcid.org/0000-0001-9247-899X
Hillman, Susan J. https://orcid.org/0000-0002-4860-671X
Lewis, Emma Grace https://orcid.org/0000-0001-9909-2731
McDonald, Claire https://orcid.org/0000-0002-7592-9952
Sloan, Katie
Suetterlin, Karen https://orcid.org/0000-0002-6505-9404
Witham, Miles D. https://orcid.org/0000-0002-1967-0990
Sayer, Avan A. https://orcid.org/0000-0003-1283-6457
-
Funding
Funding for this research was provided by:
NIHR Newcastle Biomedical Research Centre (NIHR203309)
- License Information
-
More Information
Article History
Received: 29 March 2026
Accepted: 20 May 2026
First Online: 13 June 2026
Declarations
:
: All authors report research grant funding from the National Institute for Health and Care Research. In addition, the MASS Lifecourse Study Team has a research collaboration agreement with Regeneron Pharmaceuticals, AAS reports a previous Pfizer Investigator Initiated Research Grant and MDW reports consultancy fees for the design and delivery of sarcopenia trials from Rejuvenate Biomed and Istesso.
